Vemurafenib inhibits necroptosis in normal and pathological conditions as a RIPK1 antagonist

Necroptosis, a programmed cell death with necrotic-like morphology, has been recognized as an important driver in various inflammatory diseases. Inhibition of necroptosis has shown potential promise in the therapy of multiple human diseases. However, very few necroptosis inhibitors are available for...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Mayu, Ma, Xueqi, Mu, Wei, Li, Haonan, Zhao, Xiaoming, Zhu, Tengfei, Li, Jingquan, Yang, Yongliang, Zhang, Haibing, Ba, Qian, Wang, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449909/
https://www.ncbi.nlm.nih.gov/pubmed/37620300
http://dx.doi.org/10.1038/s41419-023-06065-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449909/
https://www.ncbi.nlm.nih.gov/pubmed/37620300
http://dx.doi.org/10.1038/s41419-023-06065-8

Ejemplares similares